NewsPublic Health

Underestimating obesity

1 Mins read

Obesity Co-Morbidities

Obesity Co-Morbidities

  • Cardiometabolic syndrome
  • Type 2 diabetes
  • Hypertension
  • Dyslipidemia
  • Coronary heart disease
  • Osteoarthritis
  • Stroke
  • Gall bladder disease
  • Obstructive sleep apnea
  • Gastroesophageal reflux disease (GERD)
  • Some cancers (endometrial, breast, and colon)

Current estimates of obesity prevalence in the U.S. are based on body mass index (BMI) and account for  20% obesity rate in the 50 states, with 12 states having rates of over 30%, according to the CDC.  However, recent research carried out by researchers at New York University School of Medicine and other institutions have indicated the imprecision of BMI is resulting in a high number of false negatives for obesity.  In the research studying a sampling of men and women and comparing BMI to an alternative method for determining obesity by employing specific biomarkers and duel-energy x-ray absorptiometry (DXA), the BMI measurement concluded that 26% of the subjects were obese, while DXA concluded that 64% of the patients were obese.

Body mass index has previously been challenged as a measure of obesity due to its inability to effectively differentiate between body types regarding obesity. Whether the DXA ultimately becomes a more reliable standard measure for obesity remains to be seen, but what is clear is that any measure that results in higher counts of the obese will be met by healthcare (and the medical product industry) as justification for increased spending in the treatment of obesity. Further research, of course, will be necessary to evaluate the relationship between the increased sensitivity to detection of obesity and the identification of associated morbidity or, as is often the case with obesity, the co-morbidities of diabetes, heart disease and other expensive healthcare challenges.

For further information on obesity drugs and devices, see the 2011 MedMarket Diligence report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019”.


183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Related posts
Health careMedical EducationPublic Health

5 Compelling Reasons to See a Functional Medicine Doctor

2 Mins read
Conventional medicine has been viewed for some time now as limiting, impersonal, and too focused on symptoms rather than the root cause….

Guidelines on Choosing the Perfect Superfood Supplement

2 Mins read
There are a ton of things that you have to think about when coming up with the right diet. You probably understand…

9 Essential Compliance Guidelines for Lab Safety

5 Mins read
Now is the best time to evaluate the laboratory safety procedures. This can be a daunting task especially for large facilities, but…